HIV seroprevalence among male prison inmates in the Wisconsin Correctional System. 1998

N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
Wisconsin Division of Health, Madison, USA.

OBJECTIVE To estimate HIV seroprevalence and the acceptance of voluntary HIV testing among male inmates entering the Wisconsin Correctional System during July 1, 1994-June 30, 1995, and compare these estimates with similar data obtained in 1987-1988. METHODS A blinded HIV seroprevalence survey concurrent with a review of voluntary HIV antibody testing records. RESULTS HIV test results were obtained for 3,681 (89%) male prison entrants during the study period; 26 (0.7%) were HIV-1 seropositive. Based on this estimate and the total number of male prison entrants (4,134), an estimated 29 HIV-1 seropositive male inmates entered the Wisconsin Correctional System during the study period. Eighty-four percent of all inmates were tested voluntarily. Among inmates testing HIV-1 seropositive, 69% were tested voluntarily. CONCLUSIONS These data suggest that HIV-1 seroprevalence among male prison inmates in Wisconsin is low, and is unchanged from the late 1980s; however, a large increase in the prison population has resulted in a substantial increase in the absolute number of HIV-1 seropositive inmates entering the correctional system. Although overall acceptance of voluntary HIV testing is high, nearly one third of HIV-1 seropositive inmates declined voluntary HIV testing.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011329 Prisoners Persons deprived of their liberty; those held is against their will, or who are kept in confinement or custody. Detained Persons,Hostages,Imprisoned Individuals,Incarcerated Individuals,Inmates,Detained Person,Hostage,Imprisoned Individual,Incarcerated Individual,Individual, Imprisoned,Individual, Incarcerated,Inmate,Person, Detained,Prisoner
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014922 Wisconsin State bounded on the north by Lake Superior and Michigan, on the east by Lake Michigan, on the south by Illinois and Iowa, and on the west by Minnesota and Iowa.
D015492 AIDS Serodiagnosis Immunologic tests for identification of HIV (HTLV-III/LAV) antibodies. They include assays for HIV SEROPOSITIVITY and HIV SERONEGATIVITY that have been developed for screening persons carrying the viral antibody from patients with overt symptoms of AIDS or AIDS-RELATED COMPLEX. AIDS Serology,HIV Serodiagnosis,HTLV-III Serodiagnosis,HTLV-III Serology,Serodiagnosis, AIDS,Serodiagnosis, HIV,Serodiagnosis, HTLV-III,Serology, AIDS,Serology, HTLV-III,AIDS Serodiagnoses,HIV Serodiagnoses,HTLV III Serodiagnosis,HTLV III Serology,HTLV-III Serodiagnoses,Serodiagnoses, AIDS,Serodiagnoses, HIV,Serodiagnoses, HTLV-III,Serodiagnosis, HTLV III,Serology, HTLV III
D015528 HIV Seroprevalence Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV SEROPOSITIVITY). Seroprevalence, HIV

Related Publications

N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
September 1990, American journal of public health,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
July 2001, Annals of epidemiology,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
April 2009, Revista panamericana de salud publica = Pan American journal of public health,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
January 2003, Public health,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
April 2006, MMWR. Morbidity and mortality weekly report,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
January 1992, Journal of acquired immune deficiency syndromes,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
January 1995, Nursing times,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
July 2013, Medecine et maladies infectieuses,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
October 1990, The Western journal of medicine,
N J Hoxie, and M H Chen, and A Prieve, and B Haase, and J Pfister, and J M Vergeront
March 2009, The West Indian medical journal,
Copied contents to your clipboard!